MASLD and MASH: Steatotic liver disease joins the deadly quartet.

Authors

Risheng Xu, Nicola Abate, Rise Stribling, Richard Su

Published in

Cleveland Clinic journal of medicine. Volume 93. Issue 9. Pages 551-559. Sep 01, 2026. Epub Sep 01, 2026.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to insulin resistance and cardiometabolic disorders. This review synthesizes current information on the epidemiology, pathophysiology, and treatment of MASLD and its progressive form, metabolic dysfunction- associated steatohepatitis (MASH), underscoring how to integrate established metabolic care with emerging treatments to address the growing MASLD burden.

PMID:
42680525
Bibliographic data and abstract were imported from PubMed on 02 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.